AbbVie (ABBV) Q1 FY2026 earnings: revenue $15.0 billion, up 12.4% on the year
AbbVie Inc. (ABBV) reported revenue of $15.0 billion for Q1 FY2026, the quarter ended 31 March 2026, up 12.4% on the same quarter a year earlier. Net income was $695 million, down 46.0% on the year, and diluted earnings per share $0.39. The figures are the company's own, from the 10-Q it filed with the SEC on 8 May 2026.
Revenue
$15.0 billion
+12.4% on the year · -9.7% on the quarter
Q2 FY2024Q1 FY2026
Operating margin
26.6%
28.0% a year earlier
Q2 FY2024Q1 FY2026
Net income
$695 million
-46.0% on the year · -61.7% on the quarter
Q2 FY2024Q1 FY2026
Diluted EPS
$0.39
-45.8% on the year · -61.8% on the quarter
Q2 FY2024Q1 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Revenue
15,002
16,618
13,343
-9.7%
+12.4%
Cost of revenue
4,218
4,552
4,002
-7.3%
+5.4%
Gross profit
10,784
12,066
9,341
-10.6%
+15.4%
Gross margin
71.9%
72.6%
70.0%
Research and development
2,472
2,579
2,067
-4.1%
+19.6%
Selling, general and administrative
3,578
3,895
3,293
-8.1%
+8.7%
Operating income
3,990
4,544
3,733
-12.2%
+6.9%
Operating margin
26.6%
27.3%
28.0%
Interest expense
717
714
700
+0.4%
+2.4%
Pre-tax income
1,039
2,668
1,661
-61.1%
-37.4%
Income tax
342
853
372
-59.9%
-8.1%
Effective tax rate
32.9%
32.0%
22.4%
Net income
695
1,816
1,286
-61.7%
-46.0%
Net margin
4.6%
10.9%
9.6%
Diluted EPS
$0.39
$1.02
$0.72
-61.8%
-45.8%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
3,829
5,218
1,635
-26.6%
+134.2%
Capital expenditure
265
329
235
-19.5%
+12.8%
Free cash flow
3,564
4,889
1,400
-27.1%
+154.6%
Free cash flow margin
23.8%
29.4%
10.5%
Cash from investing
-574
-1,463
-735
Cash from financing
919
-4,166
-1,258
Depreciation and amortisation
1,936
1,922
2,039
+0.7%
-5.1%
Share-based compensation
444
157
410
+182.8%
+8.3%
Buybacks
1,489
3.0
961
+49,533.3%
+54.9%
Dividends paid
3,086
2,911
2,925
+6.0%
+5.5%
Dividend per share
$1.73
$1.73
$1.64
0.0%
+5.5%
Diluted shares, weighted
1,774m
n/a
1,772m
+0.1%
Shares outstanding at period end
1,767m
1,768m
1,766m
-0.1%
+0.0%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
-6,656
-3,270
1,420
Non-controlling interest
44.0
42.0
42.0
+4.8%
+4.8%
Debt
72,858
67,496
69,889
+7.9%
+4.2%
Operating lease liabilities
n/a
689
n/a
Finance lease liabilities
n/a
22.0
n/a
Other liabilities
70,217
68,981
64,814
+1.8%
+8.3%
Total liabilities and equity
136,463
133,960
136,165
+1.9%
+0.2%
Fixed assets
5,687
5,628
5,237
+1.0%
+8.6%
Goodwill
35,570
35,640
35,285
-0.2%
+0.8%
Intangible assets
50,873
52,641
58,489
-3.4%
-13.0%
Investments
268
296
288
-9.5%
-6.9%
Cash and equivalents
9,391
5,229
5,175
+79.6%
+81.5%
Receivables
12,479
12,589
12,477
-0.9%
+0.0%
Inventory
5,049
4,951
4,526
+2.0%
+11.6%
Other assets
17,146
16,986
14,688
+0.9%
+16.7%
Total assets
136,463
133,960
136,165
+1.9%
+0.2%
Questions
What was AbbVie's revenue in Q1 FY2026?
AbbVie (ABBV) reported revenue of $15.0 billion for Q1 FY2026, the quarter ended 31 March 2026, up 12.4% on the same quarter a year earlier.
How much did AbbVie earn in Q1 FY2026?
Net income for Q1 FY2026 was $695 million, down 46.0% on the year, and diluted earnings per share $0.39.
When did AbbVie report Q1 FY2026 results?
AbbVie filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 8 May 2026.
Each quarter as filed, linked to its filing. Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 31 March 2026, filed 8 May 2026: the filing.